Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;42(6):e3200.
doi: 10.1002/hon.3200. Epub 2023 Jun 29.

Cellular therapy in lymphoma

Anna Sureda  1 , Pieternella J Lugtenburg  2 , Marie José Kersten  3 , Marion Subklewe  4   5 , Anne Spanjaart  3 , Nirali N Shah  6 , Lucila N Kerbauy  7 , Clarie Roddie  8 , Elise R A Pennings  3 , Carolina Mahuad  9 , Michelle Poon  10 , Candice L Hendricks  11   12 , Manali Kamdar  13 , Caron Jacobson  14
Affiliations
Review

Cellular therapy in lymphoma

Anna Sureda et al. Hematol Oncol. 2024 Nov.

Abstract

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a dramatic impact on the natural history and survival of patients with high-risk B-cell non-Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T-cell therapy, written by an International community of lymphoma experts, who also happen to be women.

Keywords: CAR T‐cells; lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Neelapu SS, Locke FL, Go WY. CAR T‐cell therapy in large B‐cell lymphoma. N Engl J Med. 2018;378(11):1065.
    1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma. N Engl J Med. 2019;380(1):45‐56. https://doi.org/10.1056/nejmoa1804980
    1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B‐cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839‐852. https://doi.org/10.1016/s0140-6736(20)31366-0
    1. Nastoupil LJ, Jain MD, Feng L, et al. Standard‐of‐care axicabtagene ciloleucel for relapsed or refractory large B‐cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119‐3128. https://doi.org/10.1200/jco.19.02104
    1. Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non‐trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095‐3106. https://doi.org/10.1200/jco.19.02103

MeSH terms

LinkOut - more resources